SOD1 and amyotrophic lateral sclerosis: ASOs have seen recent success outside the cancer field, with the SOD1 targeting ASO Tofersen recently gaining US FDA approval for the treatment of SOD1-positive amyotrophic lateral sclerosis (ALS).